Beam Therapeutics (BEAM) Return on Sales (2021 - 2025)
Historic Return on Sales for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 11.62%.
- Beam Therapeutics' Return on Sales fell 48500.0% to 11.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.45%, marking a year-over-year decrease of 70600.0%. This contributed to the annual value of 5.93% for FY2024, which is 55800.0% down from last year.
- Per Beam Therapeutics' latest filing, its Return on Sales stood at 11.62% for Q3 2025, which was down 48500.0% from 12.08% recorded in Q2 2025.
- Beam Therapeutics' 5-year Return on Sales high stood at 0.45% for Q4 2023, and its period low was 33399.0% during Q1 2021.
- Moreover, its 5-year median value for Return on Sales was 6.77% (2024), whereas its average is 2283.0%.
- As far as peak fluctuations go, Beam Therapeutics' Return on Sales crashed by -287726700bps in 2021, and later surged by 333900400bps in 2022.
- Quarter analysis of 5 years shows Beam Therapeutics' Return on Sales stood at 1.27% in 2021, then plummeted by -51bps to 1.91% in 2022, then surged by 124bps to 0.45% in 2023, then tumbled by -766bps to 3.01% in 2024, then crashed by -287bps to 11.62% in 2025.
- Its Return on Sales stands at 11.62% for Q3 2025, versus 12.08% for Q2 2025 and 14.65% for Q1 2025.